Proton pump inhibitor
Rabeprazole sodium
Brand names: Pariet
Adult dose
Dose: GORD/duodenal ulcer: 20mg PO OD for 4–8 weeks. H. pylori eradication: 20mg BD with antibiotics x7 days. Maintenance 10mg OD
Route: PO
Frequency: OD-BD
Clinical pearls
- Acid-related disorders; lower CYP2C19 dependence than omeprazole
- Review need for long-term PPI annually (NICE/MHRA)
Contraindications
- Hypersensitivity
- Concurrent rilpivirine
Side effects
- GI upset
- Headache
- Hypomagnesaemia
- B12 deficiency (long-term)
- Increased fracture risk
- C. difficile infection
- Subacute cutaneous lupus erythematosus
Interactions
- Clopidogrel (less than omeprazole)
- Methotrexate
- Digoxin
- Iron
Monitoring
- Magnesium (long-term)
- Symptoms
Reference: BNF; NICE CG184; MHRA; https://bnf.nice.org.uk/drugs/rabeprazole-sodium/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021